Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey

References

• Global Initiative for Asthma. Available from: https://ginasthma.org/
   Google Scholar
• GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2007;5(9):691–706.
   Google Scholar
• Üner S, Balcılar M, Ergüder T, editors. Türkiye Hanehalki Sağlik Araştirmasi Bulaşici Olmayan Hastaliklarin Risk Faktörleri. Ankara: Dünya Sağlık Örgütü Avrupa Bölge Ofisi, T.C. Sağlık Bakanlığı; 2018.
   Google Scholar
• Allergy & Asthma Network. How severe is my asthma: classifying asthma severity. Available from: https://allergyasthmanetwork.org/news/how-severe-is-my-asthma/
   Google Scholar
• Von Bülow A, Kriegbaum M, Backer V, et al. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract. 2014;2(6):759–767.
   PubMed Web of Science ®Google Scholar
• Belhassen M, Demoly P, Bloch-Morot E, et al. Costs of perennial allergic rhinitis and allergic asthma increase with severity and poor disease control. Allergy. 2017;72(6):948–958.
   PubMed Web of Science ®Google Scholar
• Nordon C, Grimaldi-Bensouda L, Pribil C, et al. Clinical and economic burden of severe asthma: a French cohort study. Respir Med. 2018;144:42–49.
   PubMed Web of Science ®Google Scholar
• Serra-Batlles J, Plaza V, Morejón E, et al. Costs of asthma according to the degree of severity. Eur Respir J. 1998;12(6):1322–1326.
   PubMed Web of Science ®Google Scholar
• Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Respir Pract. 2017;6:2–11.
   Google Scholar
• Weiss KB, Gergen PJ, Hodgson T. An economic evaluation of asthma in the United States. N Engl J Med. 1992;326(13):862–866.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143–178.
   PubMed Web of Science ®Google Scholar
• Çelik EG, editors. Astım Tanı ve Tedavi Rehberi 2020 Güncellemesi. Ankara: BULUŞ Tasarım ve Matbaacılık Hizmetleri San. Tic.; 2020.
   Google Scholar
• Ichikawa T, Sugiura H. Essence of the Japanese guidelines for adult asthma. In: Yokoyama A, editor. Advances in asthma: pathophysiology, diagnosis and treatment. Singapore: Springer; 2019. p. 117–131.
   Google Scholar
• Matsumoto H. Treatment with anti-IgE monoclonal antibody and free IgE. In: Yokoyama A, editor. Advances in asthma: pathophysiology diagnosis and treatment. Singapore: Springer; 2019. p. 145–156.
   Google Scholar
• Abraham I, Alhossan A, Lee C, et al. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71(5):593–610.
   PubMed Web of Science ®Google Scholar
• Alhossan A, Lee C, MacDonald K, et al. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362–1370.e2.
   PubMed Web of Science ®Google Scholar
• Faulkner K, MacDonald K, Abraham I, et al. “Real-world” effectiveness of omalizumab: an updated meta-analysis of research on adults with severe allergic asthma. Expert Rev Clin Immunol. 2021;17(1):73–83.
   PubMed Web of Science ®Google Scholar
• MacDonald KM, Kavati A, Ortiz B, et al. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008–2018. Expert Rev Clin Immunol. 2019;15(5):553–569.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Li Q, Bilir PS, et al. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States. Curr Med Res Opin. 2020;36(1):23–32.
   PubMed Web of Science ®Google Scholar
• Levy AN, Ruiz AJ, Soler NG, et al. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma. 2015;52(2):205–210.
   PubMed Web of Science ®Google Scholar
• van Nooten F, Stern S, Braunstahl G, et al. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in The Netherlands. J Med Econ. 2013;16(3):342–348.
   PubMedGoogle Scholar
• Brown R, Turk F, Dale P, et al. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy. 2007;62(2):149–153.
   PubMed Web of Science ®Google Scholar
• Vennera MC, Valero A, Uria E, et al. Cost-effectiveness analysis of omalizumab for the treatment of severe persistent asthma in real clinical practice in Spain. Clin Drug Investig. 2016;36(7):567–578.
   PubMed Web of Science ®Google Scholar
• Global Asthma Network. Global initiative for asthma. Global strategy for asthma management and prevention. Chicago (IL): Global Initiative for Asthma; 2022.
   Google Scholar
• Select Statistical Service. Population proportion–sample size. Available from: https://select-statistics.co.uk/calculators/sample-size-calculator-population-proportion/
   Google Scholar
• Macrotrends. Turkey life expectancy 1950–2023. Available from: https://www.macrotrends.net/countries/TUR/turkey/life-expectancy
   Google Scholar
• Rahavi H, Taft AS, Mirzaei M. Years of life lost due to asthma in a population-based 10-year study in Yazd, Iran. Lung India. 2018;35(6):472–475.
   PubMed Web of Science ®Google Scholar
• Asthma Control Test. Available from: www.asthmacontroltest.com
   Google Scholar
• Available from: https://euroqol.org/support/how-to-obtain-eq-5d/
   Google Scholar
• Özgen Alpaydın A, Yorgancıoğlu A. Validity and reliability of “asthma quality of life questionnaire” in a sample of Turkish adult asthmatic patients. Tüberküloz ve Toraks Dergisi. 2011;59(4):321–327.
   PubMedGoogle Scholar
• EQ-5D. Index value set calculators. SPSS_value set – Germany – EQ-5D-5L [cited 2017 Sept 28]. Available from: https://euroqol.org/support/analysis-tools/index-value-set-calculators/
   Google Scholar
• Watson L, Turk F, James P, et al. Factors associated with mortality after an asthma admission: a national United Kingdom database analysis. Respir Med. 2007;101(8):1659–1664.
   PubMed Web of Science ®Google Scholar
• Turkish Statistical Institute. TÜİK istatistik veri portal. Available from: data.tuik.gov.tr/Kategori/GetKategori?p=nufus-ve-demografi-109&dil=2
   Google Scholar
• Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007;16(1):22–27.
   PubMedGoogle Scholar
• Willson J, Bateman ED, Pavord I, et al. Cost-effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting b-agonists. Appl Health Econ Health Policy. 2014;12(4):447–459.
   PubMedGoogle Scholar
• Edejer TT, Baltussen R, Adam T, et al., editors. Cost-effectiveness and strategic planning (WHO-CHOICE). Available from: https://www.who.int/choice/cost-effectiveness/en/
   Google Scholar
• Evans DB, Lim SS, Adam T, et al. Evaluation of current strategies and future priorities for improving health in developing countries. BMJ. 2005;331(7530):1457–1461.
   PubMedGoogle Scholar
• Edoka IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. Health Policy Plan. 2020;35(5):546–555.
   PubMed Web of Science ®Google Scholar
• Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess. 2013;17(52):1–342.
   PubMed Web of Science ®Google Scholar
• Lai T, Wang S, Xu Z, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;5:8191.
   PubMed Web of Science ®Google Scholar
• McQueen RB, Sheehan DN, Whittington MD, et al. Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations. Pharmacoeconomics. 2018;36(8):957–971.
   PubMed Web of Science ®Google Scholar
• Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines – recommendations on the use of biologicals in severe asthma. Eur J Allergy Clin Immunol. 2020;75(5):1023–1042.
   Google Scholar
• Jahnz-Różyk K, Lis J, Warchol M, et al. Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland. BMC Pulm Med. 2018;18(1):48.
   PubMedGoogle Scholar
• Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy. 2010;65(9):1141–1148.
   PubMed Web of Science ®Google Scholar
• Levy ML, Andrews R, Buckingham R. Why asthma still kills: the national review of asthma deaths confidential enquiry report. London: Royal College of Physicians; 2014.
   Google Scholar
• Wu AC, Paltiel D, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: results from the asthma policy model. J Allergy Clin Immunol. 2007;120(5):1146–1152.
   PubMed Web of Science ®Google Scholar
• Morishima T, Ikai H, Imanaka Y. Cost-effectiveness analysis of omalizumab for the treatment of severe asthma in Japan and the value of responder prediction methods based on a multinational trial. Value Health Reg Issues. 2013;2(1):29–36.
   PubMedGoogle Scholar